AVX 0.00% 2.5¢ avexa limited

Ann: Letter to Shareholders from the Board of Ave, page-29

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,579 Posts.
    lightbulb Created with Sketch. 300
    re: Ann: Letter to Shareholders from the Boar... Hey Bill
    i dont think it is 'clouding my mind', pls lets discuss the issues if u like...

    Drona just clearly aint the guy to run AVX or take ATC market... and i am passionate about that...

    i agree with u that i would expect him to resign...once he knows the votes are against him...

    wrt to competition, from your own admittance, the hiv market isnt your strong point, so i'm not sure your advice on this issue is too strong

    i have spoken to quite a few in the field and am confident in my thoughts, which concur with the hiv activists

    i can assure u ATC will NOT be competing much with older NRTIs, as mentioned by the current Board. Patients taking these toxic older drugs have become heavily resistant to therapy hence the introduction of a new and unburdened NRTI is a significant addition to their treatment options

    i can also assure u that ATC will not be competing against ddC, its been off the market for almost 4 yrs?!?!!! do u really want a Chairman negotiating your position who doesnt know this?

    of the other nrti, there wont be much competition with some of the older toxic nrti

    ATC has a better reported safety profile than AZT,ddI, D4T and abc

    and ATC has greater activity than those other drugs against the M184V and tams, and than 3TC, FTC and tdf (which also has the kidney problems)

    also remember US and european current approved treatment guidelines both recommend 2 nrti as the core of all treatment

    I can assure you isentress does compete with others, remember treating physicians choose drugs based on activity and safety, not on the class of inhibitor per se...

    but the letter from concerned shareholders never disputed the usefulness of the new class of drugs that isentress belongs to, in fact it is also an excellent addition to treatment options. The EGM shareholders letter was to highlight that twice a day ARVs listed for salvage therapy can still be successfully launched and make money...

    I BELIEVE ATC will get a good partner and make good money, particularly off-label, on the world hiv market...

    DRONA MUST GO FIRST

    VOTE FOR ALL RESOLUTIONS
 
watchlist Created with Sketch. Add AVX (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.